Subscribe free

HPB & Spleen ·

Advancements in Biliary Tract Cancer Therapies

Biliary tract cancers are now seeing transformative therapies that enhance patient outcomes.

  • Chemo-immunotherapy is the new first-line standard of care.
  • Targeted therapies, especially for intrahepatic cholangiocarcinoma with FGFR2 fusions, show high response rates with drugs like pemigatinib and futibatinib.
  • IDH1-mutant cholangiocarcinoma can be treated effectively with ivosidenib.

Surgeons should prioritize biomarker testing to personalize treatment strategies and overcome barriers in accessibility and resistance.

  • HER2-targeted options are also promising for patients with HER2 amplification.

Review by Lamarca A, Harding JJ and Oh DY in J Hepatol

Copyright © 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

read the whole article in J Hepatol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

Ann Surg Oncol22 Oct 2026

Pancreatic cancer: occult spread in 1 in 4

In this prospective multicenter cohort, staging laparoscopy found occult metastases in 25% of imaging-M0 patients—including 20.6% with resectable disease—potentially sparing some patients a nonbeneficial resection.

J Gastrointest Surg21 Oct 2026

Primary closure after bile duct exploration: 0.4% leak

In this 743-patient single-center series, laparoscopic bile duct exploration achieved 95.6% stone clearance with a 0.4% bile-leak rate—reassuring results for surgeons considering T-tube-free closure.

All papers in HPB & Spleen →